ArticleBMC rheumatology2025
Efficacy and safety of avacopan in the treatment of ANCA-associated vasculitis: a systematic review and meta-analysis.
Article in BMC rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Advances in Diagnosing and Managing Primary Systemic Vasculitides: A Transforming Landscape.Diagnostics (Basel, Switzerland) · 2026Article
- Management Dilemma: Myeloperoxidase (MPO)-Positive Vasculitis in a Patient With Metastatic Malignant Melanoma.Cureus · 2026Article
- Correction: Efficacy and safety of avacopan in the treatment of ANCA-associated vasculitis: a systematic review and meta-analysis.BMC rheumatology · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a dangerous autoimmune condition that usually requires high-dose glucocorticoids with immunosuppressive agents. Although effective, long-term glucocorticoid use is associated with significant toxicity. Avacopan, a selective inhibitor of C5a receptors, has emerged as a possible glucocorticoid-sparing drug for AAV, potentially offering a safer, more specific approach to treat the disease. This systematic review and meta-analysis aimed to compare the efficacy and safety of avacopan and conventional glucocorticoid-containing regimens for the treatment of AAV.
methodsA systematic search was conducted in PubMed, Embase, Scopus, and the Cochrane Library between 2000 and 2025. Post hoc subgroup analyses, randomized controlled trials, and observational reports that compared avacopan with glucocorticoid regimens in GPA or MPA patients were included. The primary outcomes were remission at week 26 and sustained remission at week 52. The secondary outcomes were relapse rates, renal outcomes, adverse events, glucocorticoid toxicity, and health-related quality of life.
resultsNine studies with 2080 patients were combined. Compared with glucocorticoids, avacopan was associated with noninferior remission rates at week 26 and significantly higher sustained remission rates at week 52 (RR = 1.02, 95% CI: 0.88–1.19). It was associated with significantly reduced glucocorticoid toxicity, fewer adverse events, and improved quality of life scores. Heterogeneity was low (I2 = 5.4%), which supported the consistency of the results.
conclusionsCompared with standard glucocorticoid treatment, avacopan appears to offer a safer alternative with similar disease control and significantly reduced toxicity. These findings suggest a potential shift towards less toxic and more personalized approaches in AAV management, though further research is warranted to confirm these benefits.
trial registrationPROSPERO CRD420251033866. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.